This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Primary Objective and Response Variable: To assess the efficacy if Rituximab relative to placebo, as measured by the time to confirmed disease progression over a 96-week treatment period and to evaluate the safety and tolerability of rituximab in subjects with PPMS. Secondary Objective(s) and Response Variable(s): The change in total volume of brain T2 lesions on magnetic resonance imaging (MRI) scan from baseline to Week 96.
Showing the most recent 10 out of 426 publications